Ashvattha Therapeutics to Present Phase 2 DME and Wet AMD Data at Clinical Trials at the Summit and MaculArt

Ashvattha will present Phase 2 data on migaldendranib, a subcutaneous therapy for DME and wet AMD, which could offer a more patient-friendly alternative to current injection-based treatments Company is exploring new technology to normalize VEGF expression, potentially enhancing both safety and efficacy of treatments for retinal and other diseases REDWOOD CITY, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therap ...